Citation Tools

Download PDFPDF

699 Interim results from a phase IB, first-in-human study of a novel complement factor h inhibitor (GT103) in patients with refractory non-small cell lung cancer (NSCLC)
Free

Download to a citation manager

Cite this article as:
Clarke J, Stinchcombe T, Crawford J, et al
699 Interim results from a phase IB, first-in-human study of a novel complement factor h inhibitor (GT103) in patients with refractory non-small cell lung cancer (NSCLC)